315 results Stibbe advises Tessenderlo Chemie NV Stibbe advised Euronext Brussels’ listed Tessenderlo Chemie NV on its proposed business combination with its reference shareholder Picanol NV. Stibbe advises on the IPO of ABN AMRO Stibbe advises ABN AMRO, Deutsche Bank and Morgan Stanley (as joint global coordinators) and the other underwriters on the IPO of ABN AMRO. Stibbe advises on the IPO of Ferrari Stibbe advises UBS and the other underwriters on the IPO of Ferrari N.V. Stibbe advises Intertrust and Blackstone Stibbe advised Intertrust and Blackstone on the IPO of Intertrust. Stibbe represents Mylan On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition Stibbe advises Kempen & Co, Degroof Corporate Finance, Bank Degroof and ING Stibbe advised Kempen & Co, Degroof Corporate Finance, Bank Degroof and ING on the private offering by NSI N.V. of 35% of its shares in Intervest Offices & Warehouses NV to a broad group of institutional and qualified investors. Stibbe advises Tessenderlo Group Stibbe advised Tessenderlo Group on the issuance and public offering of bonds to retail investors for the amount of EUR 250 million. Stibbe advises on the notes offerings of Fiat Chrysler Advising J.P. Morgan and the other underwriters on the notes offerings of Fiat Chrysler Automobiles N.V. for a total amount of USD 3.0 billion. Stibbe advises on the equity offering of Fiat Chrysler Stibbe advises J.P. Morgan and the other underwriters on the equity offering of Fiat Chrysler Automobiles N.V. Stibbe advises Tessenderlo Chemie Stibbe advised Euronext Brussels’ listed Tessenderlo Chemie NV on its EUR 175 million rights’ offering and capital increase, backed by its reference shareholder Picanol NV. Stibbe advises on the convertible bond offering of NXP Semiconductors Advising the underwriters on the USD 1 billion convertible bond offering of NXP Semiconductors Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion. Stibbe advises on the IPO of Pershing Square Holdings Stibbe advises Pershing Square Holdings, Ltd. on the IPO of this investment fund managed by the leading active investor Bill Ackmann. Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises on the IPO of IMCD Stibbe advises on the IPO of Euronext Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here. Pagination Previous page Page 15 Current page 16 Page 17 Page 18 Next page
Stibbe advises Tessenderlo Chemie NV Stibbe advised Euronext Brussels’ listed Tessenderlo Chemie NV on its proposed business combination with its reference shareholder Picanol NV.
Stibbe advises on the IPO of ABN AMRO Stibbe advises ABN AMRO, Deutsche Bank and Morgan Stanley (as joint global coordinators) and the other underwriters on the IPO of ABN AMRO.
Stibbe advises on the IPO of Ferrari Stibbe advises UBS and the other underwriters on the IPO of Ferrari N.V.
Stibbe advises Intertrust and Blackstone Stibbe advised Intertrust and Blackstone on the IPO of Intertrust.
Stibbe represents Mylan On 27 July 2015, Teva Pharmaceutical Industries announced that it has withdrawn its previously announced hostile bid to acquire Mylan N.V. Stibbe represented Mylan in this successful takeover defence and advised Mylan on both litigation and EU competition
Stibbe advises Kempen & Co, Degroof Corporate Finance, Bank Degroof and ING Stibbe advised Kempen & Co, Degroof Corporate Finance, Bank Degroof and ING on the private offering by NSI N.V. of 35% of its shares in Intervest Offices & Warehouses NV to a broad group of institutional and qualified investors.
Stibbe advises Tessenderlo Group Stibbe advised Tessenderlo Group on the issuance and public offering of bonds to retail investors for the amount of EUR 250 million.
Stibbe advises on the notes offerings of Fiat Chrysler Advising J.P. Morgan and the other underwriters on the notes offerings of Fiat Chrysler Automobiles N.V. for a total amount of USD 3.0 billion.
Stibbe advises on the equity offering of Fiat Chrysler Stibbe advises J.P. Morgan and the other underwriters on the equity offering of Fiat Chrysler Automobiles N.V.
Stibbe advises Tessenderlo Chemie Stibbe advised Euronext Brussels’ listed Tessenderlo Chemie NV on its EUR 175 million rights’ offering and capital increase, backed by its reference shareholder Picanol NV.
Stibbe advises on the convertible bond offering of NXP Semiconductors Advising the underwriters on the USD 1 billion convertible bond offering of NXP Semiconductors
Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.
Stibbe advises on the IPO of Pershing Square Holdings Stibbe advises Pershing Square Holdings, Ltd. on the IPO of this investment fund managed by the leading active investor Bill Ackmann.
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.